Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ALTH just had somemore good news. Just hit
GW
ALT, looks like a reversal here. IMO
ALTH had good news yesterday also
GW
GONT, yup pushin to .04.
GW
CLHB a monster
CLHB had good earnings, nice turnaround story. Short positions approx 25%. Can you say Squeeeeeeeeeze!
GW
CLHB good earnings, large short position approx 25%. Should be fun. In TFSM also lisp.
GW
Hey Buzz, did you get a call from DIO about supporting the board for the upcoming vote? lol I just did, but I already sold at .42. She said I could still vote, but it's already in file 13. Are they anticipating that the shareholders will not go along with the board?
GW
GOAM..I can't believe I just flipped it this morning. Ugh!!!!!
GW
FTUS breaks 2.24 it's off to ? 2.50? 2.75?
GW
CLHB any comments?
GW
LSBC can't believe I sold for a small loss about a month ago. lol
GW
PCLE have a pos. Looking for 7.50-8.00
FTUS FWIW last year they really started taking off the 2nd week of Nov if I'm not mistaking.
GW
FTUS, I'm holding the line so far due to the positive outlook given yesterday even though they had a rough Oct. I will buy on any dip under 2.
GW
Ameritrade, as a matter of fact I had all cash deployed and used DTBP to flip GOAM this am. However if I would have chosen to hold until tomorrow or Fri I could have from past experiences.
GW
Buzz. Then I must be falling under the radar. I have had all cash balance deployed with daytrading buying power $ from broker and bought sub 1.00 (even BB) stocks and even held for a day or two.
GW
Buzz, wouldn't those maintanence calls be more based upon the % that a security drops than the $5.00 PPS? A large % drop would more effect the margin acct based upon whether their is sufficient buying power to meet required maint. I buy otc on margin so the 5.00 has not effected me at all. However it does take a higher amount of available maint to buy those low PPS stocks.
GW
PMACA, did get a nice flip on it today. Also looking for 4.50 or a smidge lower. Thanks to monk for the heads up.
GW
PMACA,ADMT, FTUS (8^)
GW
DBBD, nice call on that one. Didn't play but watched it.
GW
CIO, yes watching myself. Also LFP above avg vol just up a penny. Any feel for DYX? Plus EAG I think pulls back hard tomorrow without news.
GW
Cause were so contrary I guess lol. Keep up the great picks.
GW
FTUS...Have a feeling it's headed ^ very soon.
GW
Buzz, great calls on both!
GW
Diomed Announces Record Third Quarter Revenue up 22% and YTD 2003 Revenue up 63%
YTD 2003 Revenue from EVLT(R) Procedure Kits Increases 300%
ANDOVER, Mass., Nov 4, 2003 (BUSINESS WIRE) --
Diomed Holdings, Inc. (AMEX: DIO), a leading developer and marketer of minimal and micro-invasive medical technologies, today announced 2003 financial results for the third quarter ended September 30, 2003.
For the quarter ended September 30, 2003, Diomed Holdings, Inc. delivered revenue of $2.4 million, a 22% increase over $1.9 million in the prior year. Revenue for the nine-month period ended September 30, 2003, totaled $6.6 million, an increase of 63% or $2.6 million from the same period in 2002. Importantly, revenue from EVLT(R) procedure kits increased 59% from the first quarter run rate and four times the prior year third quarter level.
James Wylie, President and Chief Executive Officer of Diomed Holdings, Inc. commented, "Diomed delivered strong financial results, and since going public, delivered record third quarter revenue, record gross margins, and record revenue from EVLT procedure kits. From a strategic standpoint, the EVLT kit revenue growth and its recurring revenue stream is key to our business model and driving Diomed to become a significant participant in the growing market for minimal and micro-invasive medical technologies."
Gross profit for the quarter ended September 30, 2003, at $832,000, an increase of $173,000 from the same period in 2002. For the nine-month period ended September 30, 2003, the Company delivered gross profit of $2.4 million, compared to $590,000 for the same period in 2002. On a percentage basis, gross margin increased from 14% to 37% during the comparable prior year nine-month period. This increase was driven primarily by increased EVLT revenue and resulting fixed manufacturing cost leverage.
EAG CC very nice so far.
GW
billy, I just have a feeling this is just starting and has a "monk" multi bagger possibility.
GW
EAG...With the news I am now thinking close of .80 or better, with 1.00+ sometime Wed. This is pretty big for this small co. IMO only, just tired of leaving lots of $$ on the table. lol
GW
BTW, anybody here in UAX?
GW
Me too! But we see criminal acts M-F on L2 52 wks a year! lol
GW
IMO this thing goes deeper, and more will be exposed soon. I thought I cashed out of funds too soon and left some $$ on the table, but I think over the next 2 weeks I'll get in again at a better price and play until 1st or 2nd week in Dec.
GW
Finally nailed that piece of garbage.
Thankfully I never fell for his promo trash.
Maybe he'll get Bubba for a cell mate and make a QBID pilot. lol
GW
UAX News:
USURF America, Inc. (Amex: UAX), a provider of wireless, high-speed broadband communications services, announced today they have signed a letter of intent to acquire Apollo Communications of Colorado Springs. Apollo has over 5,500 customers and equipment located in Denver, Colorado Springs, Pueblo and southwestern Colorado. With monthly revenues in excess of $350,000, Apollo provides data and high-speed internet services as well as local and long distance telephone services. Since Apollo holds a license to operate as a Competitive Local Exchange Carrier (CLEC) in Colorado, the transaction must be reviewed and approved by the Colorado Public Utilities Commission.
In connection with the proposed transaction, USURF has completed a series of private placements and has loaned Apollo $600,000.
"The combination of Apollo and USURF will create a stronger, more dynamic network provider that will deliver advanced communications services and value to our customers," said Bart Atkinson, president of Apollo.
"The addition of Apollo's network and operations centers in Denver and Colorado Springs will provide a higher level of support and product offerings to our customers to give us a marketing edge over our competition," said Doug McKinnon, CEO of USURF America, Inc. "This significantly expands our existing network and broadens our base of opportunities."
About USURF America, Inc.
First post. Have enjoyed the board.
CRDM looks jiggy IMO
GW
AVAN news:
NEEDHAM, Mass., Feb 26, 2003 (BUSINESS WIRE) -- AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) today reported financial results for the fourth quarter and year ended December 31, 2002. The Company reported a net loss of $3.5 million, or $0.06 per share, for the fourth quarter of 2002 compared to a net loss of $6.9 million, or $0.11 per share, for the fourth quarter of 2001. The decreased loss for the fourth quarter of 2002 primarily reflects a decrease in operating expense compared to the same period in 2001 offset in part by decreases in revenue and investment income. The decrease in revenue of $124,900 results from a reduction in licensing revenue as a result of the termination of the Novartis agreement on TP10 in transplantation in the third quarter of 2002 offset by a milestone payment received from Pfizer in late 2002. The decrease in operating expense of $3.7 million primarily results from a reduction in research and development expenses in the fourth quarter of 2002 related to 1) the Company's terminated TP10 programs; 2) a decrease in clinical trials expenses due to fewer clinical trials in progress during the fourth quarter of 2002; 3) a decrease in manufacturing costs as a result of delays in production runs for the bacterial vaccines programs; and 4) a decrease in personnel-related expenses. The decrease in research and development expenses was offset in part by an increase in facility-related expenses and increased legal, insurance and corporate communications costs. At December 31, 2002, the Company reported cash and cash equivalents of $25.1 million.
For the year ended December 31, 2002, the Company reported a net loss of $13.8 million, or $0.23 per share, compared to a net loss of $22.8 million, or $0.39 per share, for fiscal 2001. The full year results for 2002 reflect an increase in revenue combined with a decrease in operating expense compared to the same period in 2001. The increase in revenue of $3.4 million primarily results from the recognition of approximately $4.0 million in revenue upon the termination of the Novartis TP10 agreement offset in part by a reduction in product sales of Megan(R)Vac 1 and a decrease in government grant revenue recorded in 2002. The decrease in operating expense of $6.8 million is primarily due to decreased clinical trials costs and clinical materials costs incurred in connection with the company's clinical programs. It also reflects the elimination of goodwill amortization of $580,800, offset in part by an increase in consultancy, legal and facility-related expenses. The decrease in investment income of $1,205,700 reflects lower average cash balances between periods and significantly lower interest rates.
"During the past twelve months, we have achieved the following notable clinical and financial milestones," said Una S. Ryan, president and chief executive officer of AVANT Immunotherapeutics, Inc.:
-- We completed enrollment in the Phase II efficacy study with our vaccine candidate for cholesterol management, CETi-1. We expect to report results from this lengthy study in the fourth quarter of 2003. -- We also completed a Phase II dose-ranging study for our cholera vaccine candidate, CholeraGarde(TM). The study results confirm the vaccine's safety and supported the start of trials in December with the International Vaccines Institute (IVI) in Bangladesh where cholera is endemic. -- We announced the acquisition of the technology and intellectual property portfolio of Universal Preservation Technologies, Inc. (UPT), including VitriLife(R), a new technology with the potential to reduce manufacturing costs and improve product stability, eliminating the need for vaccine refrigeration. -- Finally, clinical testing began with an injectable anthrax vaccine that uses AVANT technology. Our partner, DynPort Vaccine Company (DVC), is developing this vaccine for the U.S. Department of Defense. -- We additionally announced in January 2003 a new Department of Defense subcontract from DVC that supports the development of an oral, combination vaccine against both anthrax and plague using our vectored vaccine technology. Under the agreement, AVANT may receive in excess of $8 million over a two-year period, covering vaccine development through preclinical testing.
Dr. Ryan continued, "I wish to emphasize strongly that AVANT is a company with a variety of late-stage programs in clinical development, the majority of which are supported by major companies, governmental agencies or international health organizations. In particular, we are extremely pleased to have been awarded the DVC subcontract for the development of the oral, combination anthrax and plague vaccine since it provides non-dilutive funding to the company.
Receipt of this contract means that AVANT should now have over two years of cash and cash equivalents on hand. Moreover, we are excited about using our vectored vaccine technology in support of the country's biodefense initiatives.
Dr. Ryan added, "We continue to advance CETi-1, our novel immunotherapeutic for cholesterol management, through clinical development with Phase II clinical results expected in the fourth quarter. We are supporting this current trial on our own, with the intent to partner this product for further development and potential commercialization. With our partner, GlaxoSmithKline, we are developing a two-dose oral rotavirus vaccine that is expected to enter global late-stage clinical studies in the second half of this year. Finally, we are advancing the two lead products in our bacterial vaccines portfolio, CholeraGarde(TM) cholera vaccine and Ty800 typhoid fever vaccine, in the clinic while leveraging the costs of these trials through our partners."
Clinical Development Programs
AVANT's focus is unlocking the power of the immune system to prevent and treat disease. We have assembled a broad portfolio of technologies and intellectual property that give us a strong competitive position in the vaccines arena and five of our vaccines are in clinical development. The development of immunotherapeutic vaccines like CETi-1 and the marriage of innovative vector delivery technologies with the unique Vitri(R)Life manufacturing process represent the potential for a new generation of vaccines. Our goal is to become a leading developer of such innovative vaccines that address health care needs on a global basis. AVANT expects to make substantial progress this year in advancing a number of products in its pipeline to the later stages of clinical development.
In the second half of 2003, AVANT expects its partner, GlaxoSmithKline, to initiate Phase III global clinical studies of its investigational rotavirus vaccine, Rotarix(TM), a two-dose oral rotavirus vaccine which has been shown to be helpful in preventing rotavirus gastroenteritis (RGE) disease in young children for at least two years following administration.
Also during the fourth quarter 2003, AVANT expects to announce results from a blinded, placebo-controlled Phase II study of its innovative CETi-1 vaccine in approximately 200 patients with low levels of HDL cholesterol. The objectives of the study are to evaluate the safety, immunogenicity and dose-response relationship of the CETi-1 product in patients who receive an initial immunization followed by boosters. The primary endpoint is the change in HDL cholesterol measured after the six-month booster. CETi-1 is being developed for the management of patients with low levels of HDL (high-density lipoprotein) cholesterol. As clinical data become available, AVANT plans to seek a corporate partner to complete development and to commercialize the CETi-1 vaccine.
Development of a safe, effective cholera vaccine is the first step in establishing AVANT's single-dose, oral bacterial vaccine franchise. During 2002, AVANT completed a Phase II dose-ranging study with its CholeraGarde(TM) vaccine which confirmed the safety and activity of this vaccine and supported the start of trials in December with IVI in Bangladesh where cholera is endemic. In addition, the National Institute of Allergy and Infectious Disease (NIAID) of the National Institutes of Health (NIH) and AVANT have entered into a cooperative agreement for the NIAID to conduct a Phase I in-patient dose ranging clinical trial aimed at demonstrating the safety and immunogenicity of the Ty800 typhoid fever vaccine. The trial is planned for an NIAID funded clinical site using NIAID funded clinical material. The NIAID trial seeks to confirm the safety and immunogenicity of the Ty800 oral vaccine observed in an earlier physician sponsored Ty800 vaccine study. Finally, we are developing three additional bacterial vaccines against enterotoxigenic E. coli, Shigella and Campylobacter -- all important causes of serious diarrheal diseases worldwide.
The attenuated live bacteria used to create AVANT's single-dose oral vaccines also can serve as vectors for the development of vaccines against other bacterial and viral diseases. By engineering key disease antigens into the DNA of the vector organisms, AVANT expects to be able to extend the protective ability of its single-dose oral vaccines to a wide variety of illnesses. We believe our vector technologies may prove useful for improving and expanding America's vaccine arsenal against microbial agents used in war or terrorist attacks.
AVANT is leveraging the value of its vaccine technologies into additional markets through key collaborations. In addition to our arrangements with DVC and the NIAID to develop new generations of anthrax and plague vaccines using our vectoring technologies and IVI to bring our bacterial vaccines to developing countries where they are most needed, AVANT has also partnered with Pfizer, who will apply AVANT's vaccine technologies to animal health and human food safety markets. The Pfizer research programs are making excellent progress and in late 2002 we achieved an important milestone which resulted in a modest payment to AVANT.
Modern biotechnology offers great potential for bettering health conditions worldwide. New vaccine technologies, in particular, can provide avenues to disease prevention and treatment with notable advantages over drugs in terms of patient compliance and cost. They also offer strategies to solve global health problems, to protect both civilians and military from biowarfare threats, and to increase the safety of our food supply.
Financial Guidance for 2003
Revenues
For 2003, AVANT expects revenue to be between $6.0-$6.2 million, compared with 2002 revenue of $6.7 million.
Research and Development
Research and development spending is expected to be between $10-$12 million in 2003, compared with 2002 R&D expense of $14.7 million. The change in R&D spending from 2002 to 2003 primarily reflects two factors:
(i) Spending on clinical trials will be reduced, with the primary focus in 2003 on our Phase II trial of CETi-1 for cholesterol management. We expect clinical trial costs for our bacterial vaccines program -- Phase II studies for CholeraGarde(TM) in Bangladesh and a Phase I in-patient study for Ty800, to be incurred by our partners, the IVI and the NIH; and
(ii) A significant reduction in the level of contract manufacture expense is expected in 2003 due to delays in delivery of clinical materials of CholeraGarde(TM) vaccine from Bio Sidus and the fact that NIAID is taking on manufacturing of TY800 clinical materials.
Other Operating Expenses
AVANT expects selling, general and administrative expenses, including amortization of acquired intangible assets, this year to be in the range of $5.6-$6.2 million, compared with 2002 expenses of $6.4 million. The change from 2002 primarily reflects a reduction in expected consulting services, legal and patent expenses.
Net Loss Per Shares
Basic net loss per share attributable to AVANT stock is expected to be in the range of $0.15-$0.19 this year. This projection reflects estimated weighted average shares outstanding during 2003 of 60.5 million shares.
Dr. Ryan and Mr. Catlin will host a conference call at 11:00 AM EST on Wednesday, February 26, 2003 to discuss the 2002 financial results and guidance for 2003. To access the conference call, dial 800-915-4836 (within the United States), or 973-317-5319 (if calling from outside the U.S.). An audio replay will be available immediately following the call for approximately one week and can be accessed by dialing 800-428-6051 (within the U.S.), or 973-709-2089 (if calling from outside the U.S.). The passcode for the audio replay is 286493.
The call will also be broadcast via the Company's website: www.avantimmune.com. In order to access the webcast, your PC must have a sound card, speakers and Windows Media Player software. It is recommended that you configure your PC in advance of the webcast as the software download and installation can take several minutes.
AVANT Immunotherapeutics, Inc. is engaged in the discovery, development and commercialization of products that harness the human immune system to prevent and treat disease. The company is developing a broad portfolio of vaccines addressing a wide range of applications including bacterial and viral diseases, chronic human disease, biodefense and food safety. These include single-dose, oral vaccines that protect against important disease-causing agents and a novel, proprietary vaccine candidate for cholesterol management. AVANT's goal is to demonstrate proof-of-concept for its products before leveraging their value through partnerships. Current collaborations encompass the development of an oral human rotavirus vaccine, vaccines to combat threats of biological warfare, and vaccines addressed to human food safety and animal health.
Very nice DLIA news:
dELiA*s Corp. Announces Licensing Venture; Company Receives $16.5 MillionRoyalty Advance; Group 3 Engaged As Brand Manager; Focus On Mid- And Upper-TierRetailers
NEW YORK, Feb 24, 2003 (BUSINESS WIRE) -- dELiA*s Corp. (Nasdaq:DLIA), a leading multichannel retailer to teenage girls and young women, today announced that it entered into an agreement with JLP Daisy LLC, a Schottenstein Stores Corporation affiliate, to license the dELiA*s brand on an exclusive basis for wholesale distribution in certain categories of products, including apparel, home furnishings, cosmetics and accessories.
Group 3 Design Corp., a leading brand management firm, has been retained to manage these dELiA*s-branded licensing activities. JLP Daisy has advanced dELiA*s $16.5 million in cash against future royalties generated from the licensing venture. Once JLP Daisy LLC recoups its advance plus a preferred return, dELiA*s will receive a majority of the royalty stream after brand management fees.
Stephen Kahn, dELiA*s' Chief Executive Officer, stated, "We are excited about the opportunity to open new distribution channels to expand the dELiA*s customer base and the reach of the dELiA*s brand. Group 3's efforts will be focused on distributing an array of dELiA*s product in predominantly mid- and upper-tier department stores. We believe these activities will complement dELiA*s direct (web and catalog) and specialty-store businesses. The deal also solidifies dELiA*s balance sheet while creating an opportunity to participate in a meaningful, future royalty stream. The advance proceeds from this transaction leave us well positioned to continue to run our core dELiA*s direct and retail franchises."
Mary Gleason, CEO of Group 3, commented: "dELiA*s is one of the most prominent and relevant brands with young women today. I'm excited by the incredible enthusiasm we have already received from both the vendor and retail communities. dELiA*s has the potential to become a powerhouse licensing franchise and given the timing of this transaction, we would expect to begin distributing dELiA*s products as early as this Fall."
dELiA*s was advised on this transaction by Peter J. Solomon Company.
About dELiA*s Corp.
dELiA*s Corp. is a multichannel retailer that markets apparel, accessories and home furnishings to teenage girls and young women. The company reaches its customers through the dELiA*s catalog, www.dELiAs.cOm and 68 dELiA*s retail stores.
Forward-looking statements in this press release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future results or events. The terms "believe," "expect," "intend," "anticipate" and "plan" as well as similar expressions are intended to identify some of the forward-looking statements contained in this press release. Forward-looking statements involve a number of risks, uncertainties and other factors beyond dELiA*s control, which may cause material differences in actual results, performance or other expectations. These risks include, but are not limited to, the following: continuing costs related to our restructuring initiatives in excess of our reserves for such initiatives; our ability to reduce expenses successfully; reduced service levels or product quality as a result of cost-cutting initiatives; increases in the cost of materials, printing, paper, postage, shipping and labor; our ability to leverage investments made in infrastructure through growth; our ability to obtain acceptable store sites and lease terms; our ability to open new stores in a timely fashion; adverse weather conditions; increased levels of competition; our ability to retain key personnel; downturns in general economic conditions; changes in fashion trends; decreased levels of service from third party vendors and service providers; and other factors detailed elsewhere in this press release and our most recent annual report on Form 10-K.
About Group 3 Design Corp.
Inquiring traders want to know.
GW
I could care less about A@P. Just interesting reading.
GW
jm is this true?:
http://www.siliconinvestor.com/stocktalk/msg.gsp?msgid=18617547
GW
If you have received no compensation from WTAI then you have my apologies.
GW